Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis

Platelet-derived microparticles (PDMPs) that ultimately cause vascular complications might be used as a tool to assess thrombotic areas. We identified PDMPs, high-mobility group box-1 (HMGB1) and soluble endothelial protein C receptor (sEPCR) as useful prognosis indicators for cancer-related thrombo...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2020-01, Vol.12, p.491-497
Main Authors: Yamanaka, Yuta, Sawai, Yusuke, Nomura, Shosaku
Format: Article
Language:English
Subjects:
Biological markers
Biomarkers
Blood platelets
Cancer patients
Care and treatment
cat
Chromosomal proteins
Comparative analysis
EDTA
Endothelium
Enzyme-linked immunosorbent assay
Enzymes
hmgb1
Lung cancer
Medical prognosis
Medical research
Original Research
pdmp
Prognosis
Protein C
Proteins
sepcr
Survival analysis
Thromboembolism
Thrombosis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Platelet-derived microparticles (PDMPs) that ultimately cause vascular complications might be used as a tool to assess thrombotic areas. We identified PDMPs, high-mobility group box-1 (HMGB1) and soluble endothelial protein C receptor (sEPCR) as useful prognosis indicators for cancer-related thrombosis (CAT) to evaluate the utility of PDMPs in cancer patients. We investigated 232 cancer patients: 24 (10.3%) had thrombotic complications within 6 months after their first examination. Levels of PDMP and biomarkers were measured by enzyme-linked immunosorbent assay. The levels of PDMPs, HMGB1 and sEPCR were higher in cancer patients compared with controls. In particular, these levels were significantly elevated in lung cancer patients compared with controls, and all were higher in CAT-positive patients compared with CAT-negative patients. In particular, PDMP levels in CAT-positive patients were significantly elevated compared with CAT-negative patients. PDMP levels were significantly lower in patients who lived for more than 901 days after their first examination compared with previous data. PDMP levels were positively correlated with HMGB1, and caused the dose-dependent elevation of PDMPs in vitro using platelet-rich plasma from healthy persons. The combined increase in PDMP and HMGB1 levels might be related to CAT in cancer patients. Therefore, coagulatory dysfunction may result from increased levels of these biomarkers and contribute to the poor prognosis of cancer patients.
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S236166